Dr. Michael Greenberg talks to Katie MacFarlane, President and CEO of Xintria Pharmaceutical Corporation about the FDA and its involvement in the birth of a new medication and the different rules that vitamins and herbal medications have regarding therapeutic claims.
The Birth of a Drug: Regulatory Factors in Vitamin and Herbal Therapy Claims

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Dr. Michael Greenberg talks to Katie MacFarlane, President and CEO of Xintria Pharmaceutical Corporation about the FDA and its involvement in the birth of a new medication and the different rules that vitamins and herbal medications have regarding therapeutic claims.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: IgG4-related Autoimmune Pancreatitis and Cholangitis
Updates From the 7th World Symposium Task Force
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?